• pharma
  • pharmapharma

YOU MIGHT BE INTERESTED IN

  1. Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012

    Biotech Drug Delivery Systems - Key Company Intelligence & Market Outlook to 2012

    The two major problems for biotech drugs are their mode of delivery and relative instability. The majority of delivery methods for biological drugs involve injection, which is not necessarily ideal for most indications. As the biotech sector starts to heat up, the industry has started to look for new ways of delivering these highly successful drugs.

    ...more details
  2. Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs, 2008-2020

    Live-Licensing & In-life testing: R&D Processes and Regulation for New Drugs, 2008-2020

    Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as "in-life testing" or "live-licensing". Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner.

    ...more details
  3. World market for cancer vaccines 2007-2012

    World market for cancer vaccines 2007-2012

    Previously the cancer vaccine market has consisted of HBV (hepatitis B virus) vaccines to prevent liver cancer. 2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Another HPV vaccine, Cervarix, is due to be launched in 2007...

    ...more details

REPORT

rss_Pharma.jpg...see all
Tissue Engineering & Stem Cell Technology Report 2007

Tissue Engineering & Stem Cell Technology Report 2007

  • Publication date: 28/02/2007
  • Number of Pages: 171
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!!  With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.

Tissue engineering, the manufacture of complete tissues outside of the body ready for future transplant use, is already with us, including several types of replacement skin and a cartilage substitute. The estimated market for future tissue engineered products including the regeneration of bone, cartilage, and other connective structural treatments is worth approximately $5 billion worldwide.

The report ‘Tissue Engineering and Stem Cell Technology Report 2007’ will analyse these two highly lucrative markets for you and will include:

1. An in-depth explanation of the physiology behind stem cell technology
2. A listing of over 100 companies involved and a survey of the principle companies in stem cell development
3. An examination of the products in development & the likely clinical areas for future treatments
4. An in-depth assessment of the future markets delivered to you today
5. A thorough examination of the ethical and regulatory aspects behind stem cell research
6. A detailed analysis of the financial position of the market as it stands and future projections of growth

Methodology

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic insitutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers. The author of this report has dealt with over 50+ companies and industry contacts to assist on the production of this report.

Targeted directly at you this report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in stem cell technology.

This market has grown rapidly since the isolation of embryonic stem cells in 1998. With the technologies that impact stem cells catching up to the rate of research, now is your last chance to corner a section of this market.

It is the multifaceted role of stem cells in a whole wide range of diseases that accounts for this huge potential. The diseases that stem cell technology may offer treatments for includes:

1. Parkinson’s Disease
2. Diabetes
3. Chronic Heart Disease
4. Kidney Disease
5. Liver Failure
6. Cancer
7. Spinal Cord Injury
8. Multiple Sclerosis
9. Alzheimer’s Disease
10. Gene Therapy

Why you must buy this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the tissue engineering & stem cell treatment hold promise. This report analyses the current situation in the market and assesses the potential of work that are currently in the pipeline. You and your company should be part of this market, and you could be by placing your order immediately.

Table of Contents

Chapter 1. Introduction
1.1 Introduction
1.2 Stem cells
1.2.1 History
1.2.2 Definitions
1.3 Embryonic stem (ES) cells
1.4 Embryonic germ (EG) cells
1.4.1 Embryonic stem (ES) cells versus embryonic germ (EG) cells
1.5 Adult stem cells
1.5.1 Advantages of adult stem cells
1.5.2 Disadvantages of adult stem cells
1.5.3 Adult stem cell plasticity and transdifferentiation
1.5.4 Questions about adult stem cells
1.6 Cloning
1.6.1 Therapeutic cloning
1.6.2 Reproductive cloning
1.6.3 Dolly the sheep
1.6.4 Other cloning successes
1.7 Tissue engineering
1.7.1 History
1.7.2 Progress
1.8 Conclusions
 
Chapter 2. Key players
2.1 Introduction
2.1.1 Novocell
2.1.2 ES Cell International
2.1.3 Reliance Life Sciences
2.1.4 Cytori Therapeutics
2.1.5 Intercytex
2.2 Companies that have stem cell lines currently stored at the NIH Human Embryonic Stem Cell Registry in the US
2.2.1 BresaGen 
2.2.2 Cellartis
2.2.3 Cythera/ Novocell
2.2.4 ES Cell International (ESI)
2.2.5 Geron
2.2.6 Reliance Life Sciences
2.3 Pharmaceutical industry
2.3.1 Amersham
2.3.2 Amgen
2.3.3 AstraZeneca
2.3.4 Johnson & Johnson
2.3.5 Merck
2.3.6 Novartis AG
2.3.7 Schering AG
2.4 Key companies - US
2.4.1 Aarstrom Biosciences Inc.
2.4.2  Advanced Cell Technology Inc.
2.4.3 BioE
2.4.4 Cellerant
2.4.5 Cytori Therapeutics
2.4.6 Genentech
2.4.7 Osiris 
2.4.8 Stem Cells Inc.
2.4.9 Stem Cell Therapeutics Corp
2.4.10 Titan Pharmaceuticals Inc.
2.4.11 Viacell
2.5  Key companies - UK
2.5.1 Angel BioTechnology
2.5.2 Axordia
2.5.3 Epistem
2.5.4 Intercytex
2.5.5 Novathera 
2.5.6 Odontis 
2.5.7 RegenTec
2.5.8 Reinnervate
2.5.9 ReNeuron
2.5.10 Renovo
2.5.11 Stem Cell Sciences
2.6 Key companies - global
2.6.1 Australia
2.6.1.1 Mesoblast Limited
2.6.2 Israel
2.6.2.1 Pluristem
2.6.2.2 BrainStorm Cell Therapeutics
2.6.2.3 Gamida
2.6.3 Thailand
2.6.3.1 TheraVitae
2.6.4 India
2.6.4.1 Stempeutics
2.6.5 Singapore
2.6.6 Sweden
2.7  Other companies
2.7.1 Bioheart, Inc.
2.7.2  Aldagen
2.7.3  Cellular Dynamics International
2.7.4  RhinoCyte
2.7.5  Stem Cell Innovations
2.7.6  StemCell Technologies
2.7.7  Vesta Therapeutics
2.7.8  Vistagen Therapeutics 
2.8    Conclusions
 
Chapter 3. The Market
3.1 Introduction
3.2 The Global burden of disease
3.3 Numbers of patients
3.4 Cost of illness
3.5 Major clinical applications
3.5.1 Cardiac applications
3.5.2 Other circulatory applications
3.5.3 Cosmetic applications
3.5.4 Dermatological applications
3.5.5 Endocrine applications
3.5.6 Hepatic applications
3.5.7 Neural applications
3.5.8 Optical applications
3.5.9 Orthodontic applications
3.5.10 Orthopaedic applications
3.5.11 Renal applications
3.5.12 Other applications
3.6 Regenerative medicine market
3.6.1 Stem cell market
3.6.2 Media coverage
3.6.3 Tissue engineering
3.7 Conclusions
 
Chapter 4. Issues
4.1 Introduction
4.2 Ethical Issues
4.2.1 The Ethics of how life is defined
4.2.2 The Ethics of using stem cells
4.3 Social Issues
4.3.1 Tissue source
4.3.2 Hybrids
4.3.3 Long term implications of stem cell research
4.4 Moral issues
4.5 Religious issues
4.5.1 Catholicism
4.5.2 Protestantism
4.5.3 Judaism
4.5.4  Islam
4.5.5 Hinduism
4.6 Political issues
4.6.1 US
4.7 Conclusions
 
Chapter 5. Regulations and patents
5.1 Introduction
5.2 Regulatory issues
5.2.1 UK Government initiatives
5.2.2 UK Stem cell bank
5.2.3 UK - Current regulations
5.2.4 US Government initiatives
5.2.4.1 History
5.2.4.2 Appropriations Bill, HR 3061 (Sec. 510)
5.2.5 US Current regulations
5.2.6 Ongoing controversy
5.2.7 Political landscape
5.2.8 Cell line viability
5.2.9 Xenotransplantation
5.2.10 Rest of World
5.2.11 Europe
5.2.12 Asia
5.2.12.1 Japan
5.2.12.2 China
5.2.12.3 Singapore
5.2.12.4 India
5.2.12.5 South Korea
5.2.13 Australia
5.2.14.1 Canada
5.2.14.2 South America
5.2.13 Australasia
5.2.14 Canada and South America
5.2.15 Middle East
5.2.16 Africa
5.3 Conclusions
5.4 Patenting Issues
5.4.1 Background
5.4.2 Patenting - Europe
5.4.3 Patenting - UK
5.4.3.1 Processes for obtaining stem cells from   human embryos
5.4.3.2 Human totipotent cells
5.4.3.3 Human embryonic pluripotent cells
5.4.4 Patenting - USA
5.4.4.1  Wisconsin Alumni Research Foundation   (WARF)
5.4.4.2. Geron
5.4.5 Patenting controversy
5.4.6 Patenting - global
5.5 Conclusions
 
Chapter 6. Trends, Drivers and Opportunities
6.1 Introduction
6.2 Stem Cell Research - SWOT analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 Trends
6.3.1 Portfolio diversification
6.3.2 Strong proprietary rights
6.3.3 Strategic partnerships
6.4 Drivers
6.4.1 Funding
6.4.2 Results
6.5 Opportunities
6.5.1 Suppliers to the stem cell industry
6.5.2 Cord blood banking
6.6 Conclusions
 
Chapter 7.  Stem cell research funding
7.1 Introduction
7.2 Charities and research councils
7.2.1 Wellcome Trust/ Juvenile Diabetes Research Foundation
7.2.2 Wellcome Trust/ Medical Research Council/ Wolfson Foundation
7.2.3 Juvenile Diabetes Research Foundation (JDRF)
7.3 Private funds
7.3.1 The Starr Foundation
7.3.2 Ansary Center for Stem Cell Therapeutics
7.3.3 Johns Hopkins.
7.3.4 University of Texas Health Centre
7.3.5 University of California, San Francisco (UCSF)
7.4 Public funds
7.4.1 Venture Capital
7.4.2 Other public funds
7.4.3 California 
7.4.4 New Jersey
7.4.5 Massachusetts
7.4.6 Connecticut
7.4.7 Illinois
7.4.8 Maryland
7.4.9 Ohio
7.4.10 Others
7.4.11 European Union
7.5 Conclusions
 
Chapter 8. Conclusions - the future of the stem cell market
8.1 Introduction
8.2 Progress
8.2.1 Science
8.2.2 Media
8.2.3 Geography
8.2.4 Funding
8.2.5 Patenting
8.2.6 Politics
8.3 Recommendations
 
List of tables
Table 1.1 Key achievements in stem cell research
Table 1.2 Diseases and conditions treated with adult stem cell therapies
Table 2.1 Organisations currently listed as the supplier of stem cell lines to the NIH Human Embryonic Stem Cell Registry
Table 3.1 The world top 20 threats to health in 2002 and projected 2030
Table 3.2 Number of potential patients in the US eligible for stem cell therapy 
Table 3.3 Annual direct expenditure in the US for leading diseases and conditions
Table 3.4 Top surgical and non-surgical cosmetic procedures for men and women (2005)
Table 5.1 Representative state-wide initiatives regarding the application of stem cell research
Table 5.2 EU member states legislation (2006)
 
List of figures
Figure 1.1 Number of papers published per annum (1996-2006)
Figure 1.2 Schematic of embryonic stem cell differentiation
Figure 1.3 Lung cells derived from human embryonic stem cells
Figure 1.4 Foetal neural stem cells
Figure 1.5 Schematic of embryonic tissue differentiation
Figure 5.1 Published patents (1997 - 2005), Title search: "Stem cell*", "Embryonic stem cell*" and "Human embryonic stem cell*"
Figure 5.2 Number of key patent families (2000 - 2005)
Figure 7.1 Current translation pathway for stem cell research to commercialisation

Companies Listed

Aarstrom Biosciences Inc.
Acorda Therapeutics
Advanced BioHealing, Inc.
Advanced Cell Technology Inc.
Aldagen, Inc.
American Society of Plastic Surgeons
Amersham
Amgen
Angel BioTechnology
Ansary Center for Stem Cell Therapeutics
Arthritis Research Campaign, UK
AstraZeneca
Athersys
Axordia
Bart’s and The London NHS Trust, UK
BioE
Bioheart, Inc.
Biotechnology and Biological Sciences Research Council, UK
BrainStorm Cell Therapeutics
BresaGen
Burnham Institute for Medical Research
The California Family Bioethics Council
California Institute for Regenerative Medicine
Cellartis
CellCura
Cellerant
Cellular Dynamics International
The Cellulite Clinic
Center for Stem Cell and Regenerative Medicine, Ohio
Cordlife
Cythera/ Novocell
Cytori Therapeutics
Department of Health and Human Services, US
Epistem
ES Cell International (ESI)
European Patent Office
Fisher
Food and Drug Administration, US
Gamida
Genentech
Genzyme
Geron
GlobalStem Inc
Human Fertilisation and Embryology Authority, UK
Illinois Regenerative Medicine Institute
Institute for Regenerative Medicine
Intercytex
Invitrogen
The Joan and Sanford I Weill Medical Centre
Johns Hopkins University
Johnson and Johnson
Juvenile Diabetes Research Foundation
King’s College, London
Maryland Technology Development Corporation
Mediatech Inc
Medical Research Council, UK
Medra Clinic
Memorial Sloan-Kettering Cancer Centre
Merck
Mesoblast Limited
Nabi Medspa
The National Academies, US
The National Institutes of Health, US
National Health Service
National Science Foundation
National Tax Limitation Committee
Neuronova
New Jersey Stem Cell Institute
Novartis AG
Novathera 
Novocell
Odontis 
Organogenesis
Osiris 
Pluristem
RegenTec
Reinnervate
Reliance Life Sciences
ReNeuron
Renovo
RhinoCyte, Inc.
Rockefeller University
Roslin Institute
Royal College of Obstetrics and Gynaecologists, UK
Schering AG
Sigma-Aldrich
Smith and Nephew
The Starr Foundation
Stem Cells Inc.
Stem Cell Innovations
StemCell Technologies Inc.
Stem Cell Therapeutics Corp
Stem Cell Sciences
StemCo Biomedical
Stempeutics
Tengion
TheraVitae 
Titan Pharmaceuticals Inc.
Tulane University
UK Stem Cell Bank
United States Patents and Trademark Office
University of Maryland
University of Massachusetts
University of Newcastle
University of San Francisco, California
University of Texas Health Centre
University of Wisconsin
Vesta Therapeutics Inc.  
Viacell
Vistagen Therapeutics Inc.
Wellcome Trust, UK
WiCell Research Institute, US
Wisconsin Alumni Research Foundation
Wisconsin State Laboratory of Hygiene
Wolfson Foundation, UK
World Health Organisation